Automation is central to advancing CGT manufacturing, yet the sector must reconcile technical innovation with the variability and complexity of living therapies. This session explores how automation can support reproducibility, streamline quality control, and expand production capacity without compromising adaptability.
Key Takeaways:
- Assess the role of automation in reproducibility, efficiency, and quality monitoring
- Identify integration strategies that maintain flexibility across variable manufacturing processes
- Examine how automated systems can scale therapies to meet patient demand
- Compare methods for balancing innovation with operational complexity in CGT production
- Evaluate automation’s contribution to sustainable, high-volume manufacturing models
Date: 26 March 2026
Session Chair
- Edwin Stone (Chief Executive Officer | Cellular Origins)
Speakers
- Meg Wood (Managing Director | NYBC Ventures)
- John Knighton (Vice President, API Large Molecule Development | Johnson & Johnson)
